Genetically-modified Autologous T Cells [EPC] - N0000193549
Pharmacologic Class Information
| Pharmacologic Code | N0000193549 |
| Pharmacologic Name | Genetically-modified Autologous T Cells |
| Pharmacologic Uses |
|
| Pharmacologic Concept | Established Pharmacologic Classes - [EPC] |
| Pharmacologic Concept Description | An established pharmacologic class is a term or phrase that is scientifically valid
and clinically meaningful according to the following definitions:
|
NDC Products with Genetically-modified Autologous T Cells
The table contains 3 products whose active ingredient are classified under the same pharmacologic class Genetically-modified Autologous T Cells [EPC].
| NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Status | |
|---|---|---|---|---|---|---|---|
| 0078-0846 | Kymriah | Non-Proprietary Name: Tisagenlecleucel | Injection, Suspension | Intravenous | Novartis Pharmaceuticals Corporation | ACTIVE | |
| 0078-0958 | Kymriah | Non-Proprietary Name: Tisagenlecleucel | Injection, Suspension | Intravenous | Novartis Pharmaceuticals Corporation | ACTIVE | |
| 71287-119 | Yescarta | Non-Proprietary Name: Axicabtagene Ciloleucel | Suspension | Intravenous | Kite Pharma, Inc. | ACTIVE |